Q1 2024 Earnings Estimate for Alpine Immune Sciences, Inc. Issued By Wedbush (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) – Equities research analysts at Wedbush raised their Q1 2024 earnings per share estimates for shares of Alpine Immune Sciences in a research note issued on Thursday, April 11th. Wedbush analyst R. Driscoll now forecasts that the biotechnology company will post earnings per share of ($0.45) for the quarter, up from their prior forecast of ($0.48). Wedbush currently has a “Neutral” rating on the stock. The consensus estimate for Alpine Immune Sciences’ current full-year earnings is ($1.74) per share. Wedbush also issued estimates for Alpine Immune Sciences’ Q2 2024 earnings at ($0.45) EPS, Q3 2024 earnings at ($0.46) EPS, Q4 2024 earnings at ($0.47) EPS, FY2024 earnings at ($1.84) EPS, FY2025 earnings at ($1.95) EPS, FY2026 earnings at ($2.11) EPS, FY2027 earnings at ($2.58) EPS and FY2028 earnings at ($1.17) EPS.

Alpine Immune Sciences (NASDAQ:ALPN) last posted its earnings results on Monday, March 18th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.47. Alpine Immune Sciences had a negative return on equity of 15.54% and a negative net margin of 54.66%. The firm had revenue of $30.85 million for the quarter, compared to analysts’ expectations of $6.90 million.

A number of other equities research analysts have also recently commented on ALPN. Oppenheimer restated an “outperform” rating and set a $44.00 target price (up from $33.00) on shares of Alpine Immune Sciences in a research report on Tuesday, March 19th. SVB Leerink cut Alpine Immune Sciences from an “outperform” rating to a “market perform” rating and lifted their price objective for the stock from $42.00 to $65.00 in a report on Friday. Leerink Partnrs cut Alpine Immune Sciences from an “outperform” rating to a “market perform” rating in a report on Thursday, April 11th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $65.00 price objective (up from $41.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Finally, HC Wainwright cut Alpine Immune Sciences from a “buy” rating to a “neutral” rating in a report on Thursday, April 11th. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $50.33.

Alpine Immune Sciences Stock Up 0.1 %

NASDAQ:ALPN opened at $64.42 on Monday. Alpine Immune Sciences has a 52 week low of $6.71 and a 52 week high of $64.57. The stock has a market capitalization of $4.22 billion, a PE ratio of -100.66 and a beta of 1.14. The stock’s 50-day moving average price is $37.16 and its 200-day moving average price is $23.49.

Institutional Investors Weigh In On Alpine Immune Sciences

A number of large investors have recently made changes to their positions in the stock. Royal Bank of Canada lifted its holdings in Alpine Immune Sciences by 99.1% in the second quarter. Royal Bank of Canada now owns 2,642 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 1,315 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Alpine Immune Sciences by 745.5% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,312 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in Alpine Immune Sciences in the third quarter valued at approximately $35,000. Barclays PLC lifted its holdings in Alpine Immune Sciences by 818.4% in the fourth quarter. Barclays PLC now owns 6,080 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 5,418 shares during the last quarter. Finally, BNP Paribas Arbitrage SNC lifted its holdings in Alpine Immune Sciences by 88.7% in the third quarter. BNP Paribas Arbitrage SNC now owns 6,572 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 3,090 shares during the last quarter. 75.17% of the stock is currently owned by hedge funds and other institutional investors.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.